Different Anesthetic Technique For ERCP

Sponsor
The First Affiliated Hospital with Nanjing Medical University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04087668
Collaborator
(none)
400
1
3
7
57.4

Study Details

Study Description

Brief Summary

Providing the appropriate anesthetic technique for endoscopic retrograde cholangiopancreatography (ERCP) in remote locations can be challenging. The aim of this study was therefore to prospectively assess and compare the feasibility of monitored anesthesia care (MAC) with propofol based deep sedation, standard general anesthesia and general anesthesia without neuromuscular blockade in patients undergoing ERCP.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Monitored Anesthesia Care
  • Procedure: General Anesthesia
  • Procedure: Induction Without Neuromuscular Blockade
N/A

Detailed Description

ERCP is identified as one of the most invasive endoscopic procedures, during which patients may experience anxiety, discomfort and suffer different degree of pain. So, anesthesia and analgesia are essential for this invasive procedure, especially therapeutic ERCPs. Thus, we compared the efficacy of using monitored anesthesia care (MAC) with deep sedation versus general anesthesia (GA) to perform this procedure and the incidence of complications associated with these methods of anesthesia.

Previous studies have concluded that intubation is possible without the use of neuromuscular blockade. We assume that the use of propofol and adjuvants short-acting opioids may provide adequate conditions for tracheal intubation. It was also hypothesized that it may also be useful in facilitating ERCP under general anesthesia without neuromuscular blockade.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Deep Sedation and General Anesthesia for Endoscopic Retrograde Cholangiopancreatography
Actual Study Start Date :
Jun 1, 2019
Anticipated Primary Completion Date :
Dec 1, 2019
Anticipated Study Completion Date :
Dec 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: Monitored Anesthesia Care

Patients in this arm will undergo an ERCP using monitored anesthesia care (MAC) with propofol based deep sedation.

Procedure: Monitored Anesthesia Care
MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.

Other: General Anesthesia

Patients in this arm will receive standard general anesthesia with neuromuscular blockade.

Procedure: General Anesthesia
Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .

Other: General Anesthesia Without Neuromuscular Blockade

Patients in this arm will receive nasotracheal intubation without neuromuscular blockade.

Procedure: Induction Without Neuromuscular Blockade
Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .

Outcome Measures

Primary Outcome Measures

  1. The overall complication rate [within 72 hours of ERCP]

    The primary outcome was the overall pulmonary and cardiac complication rate.

Secondary Outcome Measures

  1. Conversion to GA [During the procedure]

    Conversion to general anesthesia

  2. Temporary interruption rate of ERCP [During the procedure]

  3. Premature termination rate of ERCP [During the procedure]

  4. Procedural failure rate of ERCP [During the procedure]

  5. Procedure time [During the procedure]

  6. Anesthesia time [During the procedure]

  7. Room time [During the procedure]

    Patient room-in to room-out time in the ERCP suite ("room time").

  8. Immediate Adverse Events [within 24 hours of ERCP]

  9. Delayed Adverse Events [within 72 hours of ERCP]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18-70 years old

  • Grade Ⅰ and Ⅲ according to physical status classification system of the American Society of Anesthesiologists (ASA)

  • Coagulation function tests in normal range

Exclusion Criteria:
  • Potentially difficult airways

  • Administration of sedative or narcotic drugs in the previous 24 hours

  • Severe renal or hepatic impairment

  • Severe cardiopulmonary comorbidities (defined as American Society of Anesthesiologists physical status IV or greater)

  • Contraindications to a nasotracheal intubation

  • Coagulopathy

  • History of frequent episodes of epistaxis

  • Emergent ERCP

  • At risk for reflux and aspiration

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China 210029

Sponsors and Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

Investigators

  • Study Chair: Xiaofei Cao, The First Affiliated Hospital with Nanjing Medical University
  • Study Director: Junbei Wu, The First Affiliated Hospital with Nanjing Medical University
  • Principal Investigator: Yin Fang, The First Affiliated Hospital with Nanjing Medical University
  • Principal Investigator: Tao Qi, The First Affiliated Hospital with Nanjing Medical University
  • Principal Investigator: Jing Chen, The First Affiliated Hospital with Nanjing Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
The First Affiliated Hospital with Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT04087668
Other Study ID Numbers:
  • 2019-SR-205
First Posted:
Sep 12, 2019
Last Update Posted:
Sep 12, 2019
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The First Affiliated Hospital with Nanjing Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 12, 2019